phrykt

Rapport Therapeutics, Inc. (RAPP): who owns it and who trades it

As of Nov 16, 2026, RAPP insiders reported 72 open-market sales worth $47.2M and 11 purchases worth $22M in the last 12 months, with 1% of the sale value made under pre-set 10b5-1 plans. The largest seller was Third Rock Ventures VI, L.P. (10% owner), with $28.3M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Rapport Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RAPP

162 funds and institutions reported RAPP shares worth $2.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
Trv Gp V, LLC13.1%
ARCH Venture Management, LLC7.8%
Capital International Investors6.1%
Goldman Sachs Group Inc6.1%
BlackRock, Inc.5.6%
Cormorant Asset Management, LP5.6%
Sofinnova Investments, Inc.4.0%
Johnson & Johnson3.7%
Polar Capital Holdings Plc3.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)7.17M15.01%$299M+0%
Trv Gp V, LLC6.28M13.14%$262M-12%
ARCH Venture Management, LLC3.73M7.80%$155MNo change
Capital International Investors2.92M6.11%$122M-6%
Goldman Sachs Group Inc2.91M6.09%$121M-1%
BlackRock, Inc.2.70M5.65%$113M+8%
Cormorant Asset Management, LP2.66M5.56%$111M-10%
Sofinnova Investments, Inc.1.90M3.98%$79.4MNo change
Johnson & Johnson1.78M3.73%$74.4MNo change
Polar Capital Holdings Plc1.61M3.37%$67M-2%
Baker Bros. Advisors LP1.55M3.24%$64.5MNo change
California State Teachers Retirement System1.35M2.83%$32.5M+3951%
Vanguard Capital Management LLC1.35M2.82%$56.1M+2%
Trv Gp Vi, LLC969,2182.03%$40.4MNo change
State Street Corp818,7121.71%$34.1M+8%
Geode Capital Management, LLC793,4531.66%$33.1M+10%
T. Rowe Price Associates787,4461.65%$32.8M-9%
Perceptive Advisors LLC773,3421.62%$32.2M+15%
Vestal Point Capital, LP730,0001.53%$30.4M-49%
Alliancebernstein L.P.693,3841.45%$21.7M-5%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RAPP insiders reported $22M of open-market purchases and $47.2M of sales. 1% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$22M
11 trades, 7 people
Sales, 12 months
$47.2M
72 trades, 6 people
Sales under a 10b5-1 plan
1%
Share of sale value
Latest trade
Oct 28, 2026
Filed Oct 30, 2026

Purchases and sales by month

$22M$22MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 28, 2026James HealyDirectorPurchase952,380$21.00$20MForm 4
Oct 28, 2026James HealyDirectorPurchase6,395$21.00$134KForm 4
Oct 28, 2026James HealyDirectorPurchase3,772$21.00$79.2KForm 4
Oct 28, 2026James HealyDirectorPurchase6,933$21.00$146KForm 4
Oct 23, 2026Ramiro SanchezDirectorPurchase3,600$27.35$98.5KForm 4
Oct 22, 2026John MaraganoreDirectorPurchase8,239$26.38$217KForm 4
Oct 22, 2026John MaraganoreDirectorPurchase1,172$26.92$31.5KForm 4
Oct 22, 2026Steven M PaulDirectorPurchase35,714$27.28$974KForm 4
Oct 22, 2026Wendy B. YoungDirectorPurchase3,789$26.39$100KForm 4
Oct 22, 2026Paul M SilvaDirectorPurchase3,680$27.07$99.6KForm 4
Oct 21, 2026Abraham CeesayCEOSale plan2,210$29.16$64.4KForm 4
Oct 21, 2026Troy A. IgnelziCFOPurchase5,500$26.10$144KForm 4
Oct 7, 2026Abraham CeesayCEOSale plan1,147$30.66$35.2KForm 4
Oct 6, 2026Abraham CeesayCEOSale plan3,375$32.03$108KForm 4
Sep 30, 2026Cheryl GaultChief Operating OfficerSale plan7,925$33.04$262KForm 4
Sep 30, 2026Cheryl GaultChief Operating OfficerSale plan2,075$33.76$70KForm 4
Sep 23, 2026Abraham CeesayCEOSale43$41.05$1.8KForm 4
Sep 23, 2026Abraham CeesayCEOSale1,952$39.05$76.2KForm 4
Sep 23, 2026Abraham CeesayCEOSale215$39.86$8.6KForm 4
Sep 8, 2026Abraham CeesayCEOSale7,141$45.56$325KForm 4
Sep 8, 2026Abraham CeesayCEOSale1,069$46.01$49.2KForm 4
Aug 25, 2026Abraham CeesayCEOSale18,921$49.57$938KForm 4
Aug 25, 2026Krishnaswamy YeleswaramChief Development OfficeSale16,201$51.06$827KForm 4
Aug 25, 2026Krishnaswamy YeleswaramChief Development OfficeSale20,799$50.31$1MForm 4
Aug 24, 2026Krishnaswamy YeleswaramChief Development OfficeSale13,160$50.00$658KForm 4
Aug 19, 2026Krishnaswamy YeleswaramChief Development OfficeSale404$49.90$20.2KForm 4
Aug 11, 2026Abraham CeesayCEOSale3,664$46.90$172KForm 4
Aug 11, 2026Abraham CeesayCEOSale19,500$48.04$937KForm 4
Aug 11, 2026Abraham CeesayCEOSale5,794$48.62$282KForm 4
Aug 10, 2026Abraham CeesayCEOSale14,171$45.97$651KForm 4
Aug 10, 2026Abraham CeesayCEOSale8,370$46.75$391KForm 4
Jul 27, 2026Abraham CeesayCEOSale2,203$42.11$92.8KForm 4
Jul 27, 2026Abraham CeesayCEOSale7$42.74$299Form 4
Jul 14, 2026Abraham CeesayCEOSale2,729$40.57$111KForm 4
Jul 14, 2026Abraham CeesayCEOSale5,481$39.72$218KForm 4
Jun 30, 2026Cheryl GaultChief Operating OfficerSale1,000$43.15$43.1KForm 4
Jun 30, 2026Cheryl GaultChief Operating OfficerSale3,308$42.17$139KForm 4
Jun 30, 2026Cheryl GaultChief Operating OfficerSale1,900$40.09$76.2KForm 4
Jun 30, 2026Cheryl GaultChief Operating OfficerSale3,792$41.39$157KForm 4
Jun 29, 2026Abraham CeesayCEOSale876$40.34$35.3KForm 4
Jun 29, 2026Abraham CeesayCEOSale7,344$39.77$292KForm 4
May 26, 2026Third Rock Ventures V, L.P. +510% ownerSale18,572$40.05$744KForm 4
May 11, 2026Third Rock Ventures V, L.P. +510% ownerSale133,618$40.24$5.4MForm 4
May 8, 2026Third Rock Ventures VI, L.P. +510% ownerSale5,018$40.31$202KForm 4
May 7, 2026Third Rock Ventures VI, L.P. +510% ownerSale271,495$40.12$10.9MForm 4
Apr 17, 2026Third Rock Ventures VI, L.P. +510% ownerSale426,005$40.32$17.2MForm 4
Apr 17, 2026Krishnaswamy YeleswaramChief Development OfficeSale20,225$39.99$809KForm 4
Apr 14, 2026Krishnaswamy YeleswaramChief Development OfficeSale10,200$35.08$358KForm 4
Apr 13, 2026Krishnaswamy YeleswaramChief Development OfficeSale9,165$34.97$321KForm 4
Apr 10, 2026Krishnaswamy YeleswaramChief Development OfficeSale500$34.98$17.5KForm 4
Apr 8, 2026Krishnaswamy YeleswaramChief Development OfficeSale360$34.90$12.6KForm 4
Mar 30, 2026Cheryl GaultChief Operating OfficerSale7,161$28.04$201KForm 4
Mar 30, 2026Cheryl GaultChief Operating OfficerSale2,839$28.55$81.1KForm 4
Mar 25, 2026Krishnaswamy YeleswaramChief Development OfficeSale10,115$29.99$303KForm 4
Mar 5, 2026Cheryl GaultChief Operating OfficerSale2,014$28.93$58.3KForm 4
Feb 18, 2026Abraham CeesayCEOSale3,552$29.05$103KForm 4
Feb 18, 2026Abraham CeesayCEOSale2,100$29.80$62.6KForm 4
Feb 18, 2026Abraham CeesayCEOSale2,983$29.04$86.6KForm 4
Feb 18, 2026Abraham CeesayCEOSale2,281$29.80$68KForm 4
Feb 17, 2026David BredtChief Scientific OfficerSale2,200$29.59$65.1KForm 4
Feb 17, 2026David BredtChief Scientific OfficerSale5,400$28.95$156KForm 4
Feb 17, 2026David BredtChief Scientific OfficerSale900$28.02$25.2KForm 4
Jan 20, 2026Abraham CeesayCEOSale5,083$26.11$133KForm 4
Jan 20, 2026Abraham CeesayCEOSale5,833$26.12$152KForm 4
Jan 15, 2026David BredtChief Scientific OfficerSale8,300$26.83$223KForm 4
Jan 15, 2026David BredtChief Scientific OfficerSale200$27.40$5.5KForm 4
Dec 31, 2025David BredtChief Scientific OfficerSale6,567$30.05$197KForm 4
Dec 31, 2025Krishnaswamy YeleswaramChief Development OfficeSale2,840$30.05$85.3KForm 4
Dec 17, 2025Abraham CeesayCEOSale2,792$30.04$83.9KForm 4
Dec 17, 2025Abraham CeesayCEOSale515$31.04$16KForm 4
Dec 17, 2025Abraham CeesayCEOSale2,421$30.04$72.7KForm 4
Dec 17, 2025Abraham CeesayCEOSale2,441$28.84$70.4KForm 4
Dec 17, 2025Abraham CeesayCEOSale600$31.04$18.6KForm 4
Dec 17, 2025Abraham CeesayCEOSale2,147$28.84$61.9KForm 4
Dec 15, 2025David BredtChief Scientific OfficerSale7,704$29.95$231KForm 4
Dec 15, 2025David BredtChief Scientific OfficerSale796$30.68$24.4KForm 4
Nov 26, 2025Cheryl GaultChief Operating OfficerSale5,000$30.10$150KForm 4
Nov 17, 2025Abraham CeesayCEOSale2,242$24.91$55.8KForm 4
Nov 17, 2025Abraham CeesayCEOSale3,056$25.43$77.7KForm 4
Nov 17, 2025Abraham CeesayCEOSale2,777$24.92$69.2KForm 4
Nov 17, 2025Abraham CeesayCEOSale2,841$25.44$72.3KForm 4
Nov 17, 2025David BredtChief Scientific OfficerSale5,344$25.39$136KForm 4
Nov 17, 2025David BredtChief Scientific OfficerSale3,156$24.84$78.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Third Rock Ventures VI, L.P.10% owner–$28.3MMay 8, 2026
James HealyDirector$20.4M–Oct 28, 2026
Third Rock Ventures V, L.P.10% owner–$6.1MMay 26, 2026
Abraham CeesayChief Executive Officer, Director–$6MOct 21, 2026
Krishnaswamy YeleswaramChief Development Officer–$4.5MAug 25, 2026
Cheryl GaultChief Operating Officer–$1.2MSep 30, 2026
David BredtChief Scientific Officer–$1.1MFeb 17, 2026
Steven M PaulDirector$974K–Oct 22, 2026
John MaraganoreDirector$249K–Oct 22, 2026
Troy A. IgnelziChief Financial Officer$144K–Oct 21, 2026
Wendy B. YoungDirector$100K–Oct 22, 2026
Paul M SilvaDirector$99.6K–Oct 22, 2026
Ramiro SanchezDirector$98.5K–Oct 23, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RAPP short interest

Moderate short interest. 8.2% of RAPP shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went up 64%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.96M RAPP shares were sold short, 8.2% of the shares outstanding, up 29.7% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 1.8 trading days (days to cover).

Shares short, % of all shares

8.25%May 15Oct 308.79%

Days to cover

1.8May 15Oct 3013.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.96M8.25%+30%2.21M1.8
Oct 15, 20263.05M6.36%-4%259,51011.8
Sep 30, 20263.19M6.66%+42%660,0984.8
Sep 15, 20262.25M4.69%+1%284,2897.9
Aug 31, 20262.23M4.66%+0%271,4238.2
Aug 14, 20262.23M4.64%-1%295,7587.5
Jul 31, 20262.25M4.70%-16%299,1677.5
Jul 15, 20262.69M5.63%+19%438,9996.1
Jun 30, 20262.26M4.73%+1%488,9814.6
Jun 15, 20262.25M4.70%-9%316,6907.1
May 29, 20262.46M5.15%+2%284,8118.6
May 15, 20262.42M5.06%-21%348,7976.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Rapport Therapeutics company events

Rapport Therapeutics filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Oct 30, 2026AgreementRapport Therapeutics, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters, related to an underwritten public offering of (i) 8,333,334 shares of the Company’s common stock, par value… Filing
  3. Oct 20, 2026AnnouncementThe Company announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania. Filing
  4. Aug 5, 2026ResultsReleased financial results. Filing
  5. Jun 10, 2026VoteReported shareholder vote results. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Apr 21, 2026AnnouncementThe Company announced results from the 8-week follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures. Filing
  8. Mar 10, 2026ResultsReleased financial results. Filing
  9. Jan 7, 2026AnnouncementRapport Therapeutics, Inc. filed a prospectus supplement to the Company’s effective shelf registration statement on Form S-3 (File No. 333-288444). Filing
  10. Jan 7, 2026AnnouncementThe Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the “Investors” page of the Company’s website at www.rapportrx.com. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Rapport Therapeutics financials

Famous investors that hold RAPP

2 of the 50 well-known investors we track reported holding RAPP in their latest 13F filing. The largest position is Israel Englander's, worth $2.3M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 202668,118$2.3M0.0%-56%
Ken Griffin · Citadel AdvisorsQ3 202615,289$514K0.0%-81%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RAPP in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Cormorant Asset Management, LP13G/A5.1%
Nov 16, 2026Cormorant Asset Management, LP13G/A5.1%

Questions about Rapport Therapeutics, Inc. (RAPP) stock

Who owns the most RAPP stock?

The largest reported owner of Rapport Therapeutics, Inc. (RAPP) is FMR LLC (Fidelity), with 15.0% of the company. In total, 162 funds and institutions reported holding RAPP at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are RAPP insiders buying or selling?

In the last 12 months, RAPP insiders reported 11 open-market purchases worth $22M and 72 sales worth $47.2M. The latest trade was on Oct 28, 2026. See every trade.

What is the short interest in RAPP?

As of Oct 30, 2026, 3.96M RAPP shares were sold short, 8.2% of the shares outstanding, up 29.7% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 1.8 trading days (days to cover). See the history.

Which famous investors hold RAPP?

2 of the 50 well-known investors we track reported RAPP in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $2.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.